Iron for Health & Longevity

Created on 11/12/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Iron, an essential mineral taken orally or by infusion, is used to correct iron deficiency. In true deficiency, it restores blood levels, eases fatigue in women with low stores, relieves restless legs and, by infusion, reduces hospital stays in heart failure. Oral iron commonly causes digestive side effects. People with full stores gain nothing measurable, and build-up concerns lack trial confirmation. The evidence favors testing-guided correction over general longevity use. (Full Review)

Protocol

Deficiency confirmed first
Low ferritin or iron-deficiency anemia
Starting from ferritin testing
Alternate-day oral regimen
60 mg iron as ferrous sulfate on alternate mornings
Or 100 mg on alternate days; one dose rather than split; an empty stomach is common practice
Intravenous route
Reserved for intolerance, failed oral therapy or poor absorption
Heart failure trial: ferric carboxymaltose up to 2,000 mg, then 500 mg every 4 months
Time to effect
Hemoglobin
Within 2 weeks
Rose about 1.8–2.0 g/dL in iron-deficiency anemia
Heart failure hospitalizations
Greatest in year one
Intravenous iron, when doses are highest
Fatigue
Within 4 weeks
Daily oral iron in non-anemic women with low ferritin

Benefits

Contraindications
  • Hereditary hemochromatosis or HFE C282Y homozygosity with raised iron stores
  • Transfusion-dependent anemias such as thalassemia major
  • Children aged 1–35 months in high-malaria settings without screening
  • Known hypersensitivity to Injectafer (ferric carboxymaltose) or its components
  • Anemia without iron deficiency (normal or high ferritin; inferred from mechanism, no trial data)
Key Interactions
  • Levothyroxine
  • Levodopa (carbidopa-levodopa)
  • Tetracyclines (doxycycline, oxytetracycline, tetracycline)
  • Fluoroquinolones (ciprofloxacin, levofloxacin)
  • Cefdinir
  • Integrase inhibitors (dolutegravir, bictegravir)
  • Penicillamine
  • Carbamazepine
  • Methyldopa
  • Captopril
  • Mycophenolate mofetil
  • Proton pump inhibitors (omeprazole, pantoprazole)
  • Calcium supplements and antacids (calcium carbonate)
  • Zinc supplements
  • Tea, coffee and cocoa
Theoretical (inferred from mechanism)
  • Iron-containing multivitamins and fortified products
  • Iron chelators (deferasirox, deferiprone, deferoxamine)

Risk & Side Effects

  • High: Gastrointestinal side effects; infection with intravenous iron; severe infusion reactions with intravenous iron; hypophosphatemia after ferric carboxymaltose
  • Medium: Fatal accidental poisoning in young children
  • Low: Higher mortality with higher iron status; organ damage from overload in hemochromatosis; neurodegeneration linked to brain iron; cancer linked to higher iron stores; venous thromboembolism linked to higher iron status; type 2 diabetes linked to higher iron stores; lasting skin staining after infusion leakage; airway and esophageal injury from lodged tablets
  • Speculative:

Monitoring

Marker Target Why
Serum ferritin 50–200 μg/L Iron stores; safety check for excess
Transferrin saturation 20–50% Safety check for overload
Hemoglobin (complete blood count) 12.0–15.5 g/dL women, 13.5–17.5 g/dL men Response in anemia
C-reactive protein (CRP) Not specified in the ER Interpret ferritin
Serum phosphate (intravenous ferric carboxymaltose only) 2.5–4.5 mg/dL Safety check before repeat courses
HFE genotype (C282Y, H63D) No established target; record genotype once Safety check for overload risk

Cadence: Baseline before starting, fasting in the morning; hemoglobin at 2–4 weeks; ferritin and transferrin saturation at 8–12 weeks, then every 6–12 months while risk factors persist; phosphate before each repeat ferric carboxymaltose course; HFE genotyping once when transferrin saturation is high or a relative has hemochromatosis

Qualitative Assessment

  • Fatigue and daytime energy
  • Exercise tolerance and breathlessness on exertion
  • Restless legs symptoms at night
  • Concentration and mental clarity
  • Gastrointestinal tolerance (nausea, constipation, stool changes)